Company Analysis Sorrento Therapeutics, Inc.
1. Summary
Advantages
- Price (0.01 $) is less than fair price (0.0655 $)
Disadvantages
- Dividends (0%) are below the sector average (1.76%).
- The stock's return over the last year (-90.91%) is lower than the sector average (-28.25%).
- The company's current efficiency (ROE=-1904.94%) is lower than the sector average (ROE=13.23%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Sorrento Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -4.2% | -1.7% |
| 90 days | 0% | -31.7% | 4.4% |
| 1 year | -90.9% | -28.3% | 25.5% |
SRNEQ vs Sector: Sorrento Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -62.66% over the past year.
SRNEQ vs Market: Sorrento Therapeutics, Inc. has significantly underperformed the market by -116.38% over the past year.
Stable price: SRNEQ is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: SRNEQ with weekly volatility of -1.75% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.01 $) is lower than the fair price (0.0655 $).
Price significantly below the fair price: The current price (0.01 $) is 555% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (31.91).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (46.75).
4.3. P/BV
P/BV vs Sector: The company's P/BV (-19.26) is lower than that of the sector as a whole (3.37).
P/BV vs Market: The company's P/BV (-19.26) is lower than that of the market as a whole (-9.03).
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.64) is higher than that of the sector as a whole (3.27).
P/S vs Market: The company's P/S indicator (6.64) is higher than that of the market as a whole (4.84).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.7948) is lower than that of the sector as a whole (10.03).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.7948) is lower than that of the market as a whole (25.06).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 19.22% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (19.22%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-73.63%).
5.4. ROE
ROE vs Sector: The company's ROE (-1904.94%) is lower than that of the sector as a whole (13.23%).
ROE vs Market: The company's ROE (-1904.94%) is lower than that of the market as a whole (-8.22%).
5.5. ROA
ROA vs Sector: The company's ROA (-98.12%) is lower than that of the sector as a whole (6.16%).
ROA vs Market: The company's ROA (-98.12%) is lower than that of the market as a whole (4.87%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.76%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
